ENZON PHARMACEUTICALS INC Form 3 December 13, 2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 3 Washington, D.C. 20549 OMB

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol

(Print or Type Responses)

1. Name and Address of Reporting

Person <u>*</u> FEINSTEIN RICHARD L	rst) (Middle) 12/13/2013 TICALS,	ENZON PHARMACEUTICALS INC [ENZN]			
(Last) (First) (Middle)		4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)		
C/O ENZON PHARMACEUTICALS, INC., 20 KINGSBRIDGE		(Check all applicable)			
ROAD		Director 10% Owner X Officer Other			
(Street)		(give title below) (specify below) VP-Finance and PFO	6. Individual or Joint/Group Filing(Check Applicable Line)		

ual or Joint/Group eck Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person

4. Nature of Indirect Beneficial

Ownership

(Instr. 5)

(City)	(State)	(Zip)

PISCATAWAY, NJÂ 08854

1. Title of Security (Instr. 4)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

> Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

2. Amount of Securities

Beneficially Owned

(Instr. 4)

1. Title of Derivative Security	2. Date Exercisable and	3. Title and Amount of	4.	5.	6. Nature of Indirect
(Instr. 4)	Expiration Date	Securities Underlying	Conversion	Ownership	Beneficial Ownership
	(Month/Day/Year)	Derivative Security	or Exercise	Form of	(Instr. 5)
		(Instr. 4)	Price of	Derivative	
			Derivative	Security:	

SEC 1473 (7-02)

Table I - Non-Derivative Securities Beneficially Owned

Ownership

Form: Direct (D) or Indirect (I) (Instr. 5)

3.

OMB APPROVAL

3235-0104 Number: January 31, Expires: 2005 Estimated average burden hours per response... 0.5

Edgar Filing: ENZON PHARMACEUTICALS INC - Form 3

Date	Expiration	Title	Amount or	Security	Direct (D)
Exercisable	Date		Number of		or Indirect
			Shares		(I)
					(Instr. 5)

Reporting Owners

Reporting Owner Name / Address		Relationships				
		Director	10% Owner	Officer	Other	
FEINSTEIN RICHARD L C/O ENZON PHARMACEUTICALS, INC. 20 KINGSBRIDGE ROAD PISCATAWAY, NJ 08854		Â	Â	VP-Finance and PFO	Â	
Signatures						
/s/ Richard L. Feinstein	12/13/2013					
**Signature of Reporting Person	Date					
Explanation of Responses:						

No securities are beneficially owned

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.